TY  - JOUR
AU  - Raspollini, Maria Rosaria
AU  - Luque, Rafael J
AU  - Menendez, Carmen Luz
AU  - Bollito, Enrico
AU  - Brunelli, Matteo
AU  - Martignoni, Guido
AU  - Montironi, Rodolfo
AU  - Cheng, Liang
AU  - Blanca, Ana
AU  - Baroni, Gianna
AU  - Minervini, Andrea
AU  - Lopez-Beltran, Antonio
PY  - 2016
DO  - 10.1016/j.humpath.2016.06.022
UR  - http://hdl.handle.net/10668/10314
T2  - Human pathology
AB  - High-grade papillary urothelial carcinoma with subepithelial connective tissue invasion (T1HG) is an aggressive disease at high risk of progression after transurethral resection/Bacillus Calmette-Guerin standardized therapy. The European Organization...
LA  - en
PB  - Elsevier
KW  - Bladder cancer
KW  - E-cadherin
KW  - Progression
KW  - Survivin
KW  - T1
KW  - Topoisomerase-IIα
KW  - p16
KW  - Aged
KW  - Antigens, CD
KW  - Antigens, neoplasm
KW  - Biomarkers, tumor
KW  - Cadherins
KW  - Carcinoma, papillary
KW  - Cyclin-dependent kinase inhibitor p16
KW  - DNA topoisomerases, type II
KW  - DNA-binding proteins
KW  - Disease-free survival
KW  - Europe
KW  - Female
KW  - Humans
KW  - Immunohistochemistry
KW  - Inhibitor of apoptosis proteins
KW  - Kaplan-Meier estimate
KW  - Male
KW  - Neoplasm grading
KW  - Predictive value of tests
KW  - Proportional hazards models
KW  - Reproducibility of results
KW  - Survivin
KW  - Time factors
KW  - Treatment outcome
KW  - Tumor burden
KW  - Urinary bladder neoplasms
TI  - T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-IIα, survivin, and E-cadherin.
TY  - research article
VL  - 57
ER  -